| Réf | Country | Year | Study population | Eff | Dosimetric protocol | Limitations of the study |
| 4 | Tunisia | 2016 | Hyperthyroids under 19 years old. | 33 | NS* | Exclusively pediatric study |
| 5 | Ghana and Nigeria | 2016 | Hyperthyroid patients from two Ghanaian and Nigerian public hospitals. | 94 | Before 2010: single fixed dose of 10 mci. After 2010: fixed dose according to hyperthyroidism. | Change of dosimetric protocol |
| 6 | Morocco | 2017 | Graves disease | 50 | Empirical dose according to UTV, age, socioeconomic level. | Basedow alone |
| 7 | Morocco | 2017 | Hyperthyroidism of all etiologies | 77 | Ablative fixed dose | No mid-term hormonal assessment |
| 8 | Tunisia | 2017 | Graves disease | 70 | Ablative fixed dose | No short-term evaluation (3 months). |
| 9 | Morocco | 2019 | Hyperthyroidism of all etiologies | 208 | NS* |
|
| 10 | Tunisia | 2017 | Post-ARI evaluation of two groups of hyperthyroid patients: Basedowian subjects and toxic nodules. | 78 | NS* | Excluding GMNTs |
| 11 | Morocco | 2018 | Evaluation of the therapeutic response after ARI | 78 | Ablative fixed dose | Selection bias (Basedow only) |
| 12 | Algeria | 2019 | Description of clinical cases | 02 | Empirical dose according to UTV | Selection bias |
| 13 | Cameroon | 2019 | Review of 4 years of ARI and selection of patients who received ablative doses | 74 | Empirical dose according to UTV | Consideration of ablative doses |
| 14 | Senegal | 2020 | Population of hyperthyroid patients who received an ablative dose | 66 | Fixed dose | Preliminary study |
| 15 | Tunisia | 2020 | Hyperthyroidism secondary to Graves’ disease | 54 | Fixed dose | Exclusion of ATs and GMNTs |
| 16 | Tunisia | 2020 | Hyperthyroid patients with analysis of predictive factors for the result of the ARI | 41 | NS* | Dosimetric protocol not defined |